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Brain Tumors in Man and Animals:
Report of a Workshop*
This report summarizes the results of a workshop on brain tumors in man and animals. Animals,
especially rodents are often used as surrogates for man to detect chemicals that have the potential to
induce brain tumors in man. Therefore, the workshop was focused mainly on brain tumors in the F344
rat and B6C3F1 mouse because of the frequent use of these strains in long-term carcinogenesis studies.
Over 100 brain tumors in F344 rats and more than 50 brain tumors in B6C3F1 mice were reviewed and
compared to tumors found in man and domestic or companion animals. In the F344 rat, spontaneous brain
tumors are uncommon, most are ofglial origin, and the highly undifferentiated glioblastoma multiforme,
afrequent tumorofman was notfound. In the B6C3F1 mouse, brain tumors are exceedingly rare. Lipomas
of the choroid plexus and meningiomas together account for more than 50% of the tumors found. Both
rodent strains examined have low background rates and very little variability between control groups.
Introduction
Cancer ofthe central nervous system is ofinterest to
toxicologists because of its reported association with
various occupations in man. Rodents are often used as
models for detecting possible environmental carcino-
gens, yet systematic consideration of brain pathology
in long-term rodent carcinogenicity did not receive the
attention it deserved. It was this aspect that prompted
the National Toxicology Program to convene a confer-
ence on brain tumors on September 5 and 6, 1984, in
Research Triangle Park, NC. The conference was fo-
cused oncomparative aspectsofhumanand animalbrain
tumors and on newer techniques that can be used as
diagnostic aids for detecting and classifying brain tu-
mors. The main themes ofthe conference were: normal
structure of the brain and aids to anatomic pathology
ofbrain lesions; incidences, clinical diagnosis, and mor-
phological classification ofbrain tumors in man and an-
imals; and experimentally induced brain tumors and in
vitro studies.
Experts in human and veterinary neuropathology
presented the state-of-the-art in these different areas.
The conference wasattendedbyapproximately 150gov-
ernmental and nongovernmental scientists.
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Damon R. Averill, Jr., Sandra H. Bigner, Gary A. Boorman, Peter
C. Burger, Yancey Gillespie, Gene B. Hubbard, Ole D. Laerum,
Rodney D. McComb, John T. McGrath, Kevin T. Morgan, Alan Pe-
ters, Lucien J. Rubinstein, Bruce S. Schoenberg, S. Clifford Schold,
James A. Swenberg, Morrow B. Thompson, Marc Vandevelde, and
Stanley A. Vinores. See Appendix for affiliations and addresses of
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Incidence of Brain Tumors in Man
and Animals
Man
Descriptive epidemiologic studies ofprimary nervous
system neoplasms in well defined human populations
have demonstrated that despite our diagnostic sophis-
tication, current incidence rates probably underesti-
mate the magnitude of this health problem. Despite
variations among the different data resources in re-
porting and diagnostic practices, a general pattern of
age-specific incidence rates has emerged: a small peak
in childhood, followed by a higher peak reaching a max-
imum between ages 60 and 80 and then declining after
those ages. One notable exception to the pattern is pro-
vided by tabulations for Rochester, Minnesota, where,
after a small childhood peak, there is a sustained in-
crease in the incidence rate with increasing age. The
relatively large proportion of cases first diagnosed at
autopsy in Rochester accounts, in large part, for the
different age-specific incidence curves, particularly
among the elderly. The results of the Rochester, Min-
nesota, investigations suggestthat substantial numbers
of asymptomatic tumors are never diagnosed in older
individuals and if autopsy rates increase, the age-spe-
cific pattern ofincidence rates will more closely resem-
ble the Rochester curve.
The various histologic types of brain tumors reveal
sufficiently distinct epidemiologic patterns to be class-
ified as separate diseases. It may be misleading to con-
sider primary intracranial neoplasms as a single group,
since theoverallpicture simplyreflectsthese distinctive
individual patterns and the relative frequency of diag-SOLLEVELD ET AL.
nosed cases of these histologically separate neoplasms
in the population under study. In children, the relative
frequencies of these various tumors differ markedly
from their frequencies among adults. For example,
while medulloblastoma is the most commonly occurring
brain tumor among children, it is relatively rare in
adults. Astrocytoma is second in children, whereas it
ranks third in frequency among adults. Glioblastoma
multiforme, rankingthird in children, accountsformore
than halfofthe histologically confirmed intracranial tu-
mors among adults. Pituitary chromophobe adenoma,
while common among adults, is observed much less
often in children. Meningioma, which ranks second in
adults, is relatively infrequent in childhood.
The rare familial aggregation of certain primary in-
tracranial neoplasms and their association with condi-
tions demonstrating a defined pattern of inheritance
identify the high-risk patient. Such identification is of
immediate clinical value in alerting the physician to the
likely presence of these tumors. Recent analytic epi-
demiologic investigations have focused on potential eti-
ologic factors within the occupational environment,
whereas othershaveutilized amoregeneralexploratory
approach in searching for such factors. It is hoped that
the more detailed evaluation ofpatients at high risk for
brain tumors will lead to a better understanding ofthe
mechanisms involved in oncogenesis within the nervous
system.
Domestic Animals
With the exception ofa few sporadic reports, little is
known about brain tumors in most animal species. Only
domestic animals and laboratory animals have been suf-
ficiently studied to evaluate frequency and spectrum of
tumors ofthe nervous system. Published estimates in-
dicate thatthe frequency ofbrain tumors in all domestic
animals combined is low, whereas intracranial neo-
plasms are a relatively common finding in dogs (1-3).
The incidence rate (number of cases per 100,000 ofthe
population at risk) of nervous system tumors has been
estimated in dogs and cats to be 14.5 and 3.5, respec-
tively.
The frequency of various tumor types in specific do-
mestic animal species was estimated on the basis ofour
own material and analysis of the literature since 1968.
Atotal of1412 intracranial tumors (includingmetastatic
and pituitary growths) were found which were distrib-
uted among the various species as follows: 984 dogs,
216 cats, 68 bovines, 20 horses, 12 sheep, and 10 pigs.
Thus, braintumors are much more commonindogsthan
in other species, although-at least in our own mater-
ial-the number ofdogs necropsied is not greater than
that of food animals. The low number of brain tumors
in horses in this series is in part related to the small
overall numberofhorses examinedbut isalso consistent
with old publications in which large numbers of horses
with neurologic disease were studied. The apparent low
incidence in food animals is certainly related to their
very low life expectancy.
Only 20 tumors were available in the horse with 12
primary brain tumors consisting of 3 neuroectodermal
and 9 mesenchymal neoplasms. Of the 68 bovine brain
tumors surveyed in cattle, 26 were neuroectodermal,
including 6 medulloblastomas, and 34 were primary
mesenchymal growthsincluding20meningiomas. Inthe
other food animal species (sheep, goat, pig) only 3 neu-
roectodermal and 10 mesenchymal tumors were found.
Of the 216 brain tumors surveyed in cats, only 10 neu-
roectodermal but 148 mesenchymal tumors including
117 meningiomas were found.
The dog has not only the highest frequency of intra-
cranial neoplasms but also the broadest spectrum of
types many of which are very similar to human brain
tumors. There is a higher incidence among certain
breeds, such as boxers, Boston terriers and bulldogs.
Primary neuroectodermal and mesenchymal tumors ap-
pear to occur with similar frequency. Meningiomas and
sarcomas are well represented and are rather ill-de-
fined. Some of these latter lesions are histiocytic lym-
phosarcomas, whereas others may be true histiocytic
tumors or even granulomas.
The canine neuroectodermal tumors in our survey
consisted of92 astrocytomas, 99 oligodendrogliomas, 42
choroid plexus papillomas, 40 glioblastomas, 20 med-
ulloblastomas, 19 ependymomas, 4 gliomatosis, 1 pi-
nealoma, and 24 unclassified gliomas. The results ofim-
munocytochemical staining for the glial fibrillary acidic
protein (GFAP) in 74 canine neuroectodermal tumors
confirmed that many canine glioma types are very sim-
ilar to human brain tumors but also indicated a higher
proportion of undifferentiated gliomas in dogs as com-
pared to man.
Laboratory Animals
Awide variety ofanimal species are used in biological
and clinical research. The choice of the animal species
is dependent on the type of research carried out and
varies from primates to protozoa. This overview is con-
fined to those animal species that are most commonly
used in biomedical and toxicological studies. These are
in decreasing order of frequency: rats, mice, Syrian
hamsters, dogs, rabbits, monkeys, guinea pigs, and
cats. Brain tumors indogs and cats are discussed above.
A review ofthe literature on the occurrence ofbrain
neoplasms in the above-mentioned animal species re-
veals a variety of incidence within and among the spe-
cies. Reasons accounting for these variations are: dif-
ferencesinages oftheanimalsinthestudies, differences
in breeds, strains, substrains and stocks studied, and
differences in the extent in which brain tissue is ex-
amined.
The most valuable information on the occurrence of
brain tumors in various animal species comes from stud-
ies in which animals are allowed to live out their life-
span. Since nearly all lifetime studies are confined to
mice andrats, theincidencesinthesetwoanimalspecies
are probably the most reliable figures available from all
animal species studied so far.
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Table 1. Brain tumor incidence in various mouse strains and
hybrids.'
Strain No. of mice studied Incidence, %
VM 9,980 1.7
BRVR 2,640 1.1
C57BL 11,900 0.02
C57BL/6J 817 0.12
BALB/c 4,278 0.09
BALB/c 2,560 0.04
B6C3F1 5,065 0.08
B6C3F2 334 0.29
aModified from Swenberg (4).
Brain neoplasms in mice are exceedingly rare with
exception oftwo strains and their crosses, the VM and
BRVR (4). The respective incidences in these two
strains are 1.6 and 1.1%. Astrocytomas constitute
nearly 100percentoftheintracranialneoplasmsinthese
two strains. In all other mouse strains studied so far,
the incidence does not exceed 0.3% (Table 1). If one
excludes the two mouse strains and their crosses that
have an unusually high occurrence ofbrain tumors, the
overall incidence in mice is less than 0.01%.
Brain tumors in rats are much more common than in
mice. Data derived from lifetime studies show inci-
dences up to 7.1% (Wistar AF/Han-EMD strain) (Table
2). The F344 rat which is widely used in carcinogenesis
testingprograms in the U. S. and abroad shows lifetime
incidences of 2.9 and 2.2% in males and females, re-
spectively. The incidence at 2-year of age is 1.1% in
both sexes, but the incidence varies from 0 to 4% in
control groups of 50 animals each.
As mice, the incidence of brain neoplasms in Syrian
hamsters is exceedingly rare. As far as is known, no
reports on spontaneous brain tumors have been pub-
lished in this animal species. Lifetime data of the Na-
tional Toxicology Program show two astrocytomas in
457 male (=0.4%) and none in 463 female Syrian ham-
sters examined.
Neuroepithelial tumors have not been reported in
Table 2. Brain tumor incidence and most common tumor type in
various rat strains: lifetime studies.
Incidence (%) in Most common
Strain Males Females tumor type Reference
WAG/RIJ 2.4 3.9 Astrocytoma Burek, 1978 (48)
AF/Han- 7.1 3.3 Granular cell Sumi et al., 1976
EMD tumor (49)
ACI/seg 2.7 NS1 Granular cell Ward et al., 1983
HapBR tumor (29)
BN/BIRIJ 2.7 5.9 Granular cell Burek, 1978 (48)
tumor
Osborne- NSa 1.5 Ependymoma Dagle et al., 1979
Mendel (50)
Sprague- NSa 1.3 Astrocytoma Dagle et al., 1979
Dawley (50)
F344 0.0 NSa Coleman et al.,
1977 (51)
F344/N 2.9 2.2 Astrocytoma Solleveld et al.,
1984 (52)
aNS = not studied.
rabbits and guinea pigs and only rarely in monkeys.
Since lifetime studies dealing with these animal species
are lacking, the paucity of brain neoplasms in these
species does not necessarily mean that they are more
resistant to the development of brain neoplasms than
other species.
Clinical Diagnosis of Brain Tumors
in Man and Animals
Man
Although methods ofdiagnosis ofprimary brain neo-
plasms in humans have become increasingly sophisti-
cated, the first step in making such a diagnosis remains
the alert clinician's suspicion of the problem. Appro-
priate studies can then be used to examine particular
areas ofthe nervous system. The clinician must be sen-
sitive both to worrisome signs and symptoms and to the
epidemiology of these conditions. For example, later-
alized headaches in a 50-year-old woman should make
one concerned about a supratentorial mass, such as a
meningioma or high-grade glioma, whereas headaches
and vomiting in a 10- year-old boy should lead one to
suspect a posterior fossa mass, such as a medulloblas-
toma.
Two general categories of signs and symptoms may
be present in patients with intracranial mass lesions.
Typical symptoms produced solely bythe mass and con-
sequent increased intracranial pressure are headache
(often worse in the recumbent position) and confusion.
Signs include papilledema and altered mental status
(such as lethargy, stupor, or coma). Vomiting and hic-
coughs are also occasionally present. The other general
category of symptomatology in these patients includes
those findings that reflect dysfunction of particular
areas ofthebrain, such ashemiparesis, hemianesthesia,
visual field loss, aphasia, and focal seizures. The more
circumscribed the neurologic abnormality, e.g., a par-
ticular form ofaphasia or weakness confined to one ex-
tremity, the more precisely one can localize the path-
ologic process.
However, in this era, clinical suspicion and diagnostic
acumen merely aid in the choice and technique of im-
aging studies. These include radiographic, or X-ray,
studies as well as a variety of highly sensitive nonra-
diographic imaging techniques. Radiographic methods
include skull X-ray, angiography, pneumoencephalog-
raphy, cisternography with positive-contrast media,
and finally, computerized tomography (CT). Many of
these tests are now virtually obsolete with the advent
ofCT and nuclear magnetic resonance (NMR) imaging.
Nevertheless, all have been useful and many are still
important in certain situations. The most valuable im-
aging technique that is widely available for diagnosing
brain tumors is CT. Its sensitivity varies with both the
nature and size ofthe lesion. Primary brain tumors are
usually hypodense in comparison to normal brain, and
they show variable enhancement after intravenous in-
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fusion of a contrast agent. The degree of enhancement
reflects disruption ofthebloodbrainbarrierandtosome
extent correlates with the degree ofanaplasia. Central
low-density, nonenhancing areas within high-grade
gliomas reflect necrotic tissue (5). The full potential of
NMR in the diagnosis of primary brain tumors is un-
certain. Thisnonradiographicimagingtechniqueutilizes
differential magnetic relaxation properties of different
tissues (6). It is apparent that it is more sensitive than
CT in detecting small or subtle lesions. It is also more
useful in areas that are difficult to visualize by CT such
as the posterior fossa. Specificity of the abnormalities
on NMR remains to be determined.
Although imaging techniques have become highly el-
egant and sophisticated, it remains true that the path-
ologic specimen is the sine qua non oftumor diagnosis.
Without tissue the diagnosis is speculative, and in dif-
ficult cases the burden of proof should reside with the
physician who wishes to treat without tissue. The path-
ologic specimen is usually obtained by open and wide
resection ofthe lesion. However, when resection is not
advisable, needle biopsy under stereotactic control is
feasible, safe, and usually provides adequate material
for diagnosis. Although tissue sampling is necessarily
limited and relief of symptoms cannot be anticipated,
needle biopsy is an important advance since it provides
material for accurate diagnosis and prognosis.
Domestic Animals
Primary brain tumors occur in all the domestic ani-
mals but the dog and cat are those studied most care-
fully. Primary brain tumors in these animals comprise
nearly 4% of admissions at institutional urban veteri-
naryneurologyservices. UntilCTbecameavailable, the
history, neurologic examination, spinal fluid examina-
tion, plain radiography, electroencephalography, arte-
riography, and pneumoencephalography were the tools
in tumor localization. These methods could determine
the rostro-caudal and medio-lateral neuraxial position
of tumors with moderate accuracy, but prosencephalic
masses were often localized with insufficient precision
for surgical intervention.
The CT is now widely accepted as the tool of choice
for imaging intracranial tumors in dogs and cats and
the first reports ofindividual cases and case series have
appeared in the recent clinical literature. Meningiomas,
a variety of astrocytomas, metastatic tumors and pi-
tuitary tumors have been studied in plain and contrast-
enhanced CTs. These studies also allow assessment of
accompanying cerebral edema, midline shift, ventricu-
lar compression or hydrocephalus. Variations in the ap-
pearance of tumors on CT parallel these reported for
humans.
This technology has resulted in such an improvement
in the precision of tumor localization that biopsy and
excision are now common in the larger services. This
has resulted in improved clinical care and the availa-
bility ofneoplastic tissue for further study.
Laboratory Animals
NMR imaging is one ofthe most exciting and rapidly
developing fields in diagnostic medicine (6-8). In 1946,
the principles ofmagnetic resonance for liquids and sol-
ids were independently described by Bloch and Purcell
(9-11). These efforts earned each a Nobel prize in 1952.
In 1973, Lauterbur (12) published the first two-dimen-
sional, proton NMR image of a container of water. In
the few years since, prototype imaging devices that
were developed for use with laboratory animals have
been replaced by whole body NMR imaging systems.
Clinical trials have been conducted evaluating the po-
tential ofNMR imaging as an independent technique or
comparing it with the established technique of X-ray
CT. Because ofthe accumulated knowledge concerning
the acquisition and interpretation of CT scans of the
brain, this organ has often been used for evaluation of
NMR and CT capabilities (13-16).
NMR imaging does not use ionizing radiation to pro-
duce the cross-sectional pictures. Instead, it relies upon
the inherent property ofthosenuclei with acombination
of an odd number ofprotons and neutrons to possess a
net angular momentum or spin. Charged particles with
linear velocity generate a magnetic field that is perpen-
dicular to the direction of movement. Similarly, nuclei
with net rotation or spin have charge (protons) and an-
gular velocity. They behave, therefore, as small rotat-
ingmagnetswiththemagneticfieldbeingperpendicular
to the angle of rotation. Among those elements in the
bodysusceptibleto NMR probing, thehydrogennucleus
(proton) is the most abundant (body by weight, 60-90%
water) and has the highest degree of NMR sensitivity.
Normally, protons are randomly arranged and there is
no net magnetization in the tissue. Ifplaced in a static,
external magnetic field, however, protons align parallel
(low energy state) or antiparallel (high energy state) to
the axis ofthe static magnetic field and consequently a
macroscopic magnetization vector is produced in the
tissue. The protons do not align exactly with the static
field, but are at a slight angle to the axis about which
they rotate or precess. The frequency of precession is
directly related tothe strength ofthe externalmagnetic
field. This frequency, which is in the radiowave range,
is the source of the signal used for generation of the
NMR images. By applying a radiofrequency (RF) pulse
which matches the precessional frequency ofthe nuclei
and which rotates perpendicularly tothe staticfield, the
macroscopic magnetic vector can be tilted from its orig-
inal plane and acquire a transverse component. When
the RF signal is turned off, the nuclei spin briefly in the
altered plane and then return to the previous alignment
in the static field. An oscillating voltage (induced by the
transverse magnetization vector) is produced in a re-
ceiver coil located in the transverse plane. The fre-
quency of this "signal" is the same as the precessional
frequency of the protons.
The realignment process is characterized by two time
constants, Ti and T2. Ti, or the spin-lattice relaxation
time, is a measurement of the time required for the
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nuclei to return to longitudinal alignment in the static
field at the end of a transverse RF pulse. T2, or the
spin-spin relaxation time, reflects the time required for
disappearance ofthe transverse component ofthe mag-
netic moments ofthe nuclei duringthe realignment pro-
cess. Ti is influenced by the interaction ofthe precess-
ing nuclei with the surroundings of lattice while T2 is
influenced by the homogeneity of the static magnetic
field and by interactions between precessing nuclei. Be-
cause of these relationships, Ti values for pure water
or for water containing other small molecules are long
and those for water containing large molecules (such as
tissue fluids with proteins, fats and complex carbohy-
drates) are relatively short. T2 values are longer for
liquids than they are for solids, and with liquids, the
values decrease as larger molecules are added. In a Ti-
weighted NMR image of the brain, subcutaneous fat
appears bright (short T1), and white matter, grey mat-
ter, and cerebrospinal fluid (CSF) appear progressively
darker (increasing Ti values). Generally, the NMR sig-
nal becomes stronger (image becomes brighter) with an
increase inmagneticfield strength, anincreaseinproton
density, a decrease in Ti, an increase in T2, and a de-
crease in motion (flow).
Different NMR imaging techniques can be used such
that combinations of proton density, Ti, T2, and flow
characteristics can be emphasized. In the production of
NMR images of the brain, those techniques that mea-
sureprotondensityandTi provideexcellentgrey-white
matter contrast and good anatomical detail. T2-
weighted images of the brain have less contrast than
Ti-weighted images. Various pathologic processes in
the brain have been evaluated by NMR i.- aging. These
include infection, infarction, hemorrhage, degenerative
diseases, psychological disorders, and neoplasms. Con-
cerning the latter, some generalizations can be made.
NMR images are often equal to orbetter than CT scans
at detectingand delineating aneoplasm. Detection with
CT scans depends upon differences in tissue density.
NMR images incorporate differences in proton density
and alterations in tissue water or fat composition pro-
duced by a disease process. NMR imaging techniques
that emphasize Ti and T2 values usually permit the
distinction ofa neoplasm from normal host tissue. Gen-
erally, Ti values are increased for neoplasms (darker
on image) and malignant tumors often have longer Ti
values than benign ones. Overlapping values between
tumor types occur too frequently, however, to permit
any histologic classification based only on imaging in-
formation. Also, Ti and T2 values for tumors are not
unique and can overlap those for other types oflesions.
Additional data must be considered before a presump-
tive diagnosis of neoplasia can be made. The scientific
application of NMR imaging for the detection of brain
tumors in laboratory animals is the same as that for
human beings. For animals such as the rat or mouse,
the limiting factor is the size of the brain and the re-
sulting difficulty in resolution. Forlarger animals (e.g.,
dogs, cats, primates) brain size is not a limiting factor.
With the production of stronger magnets with more
homogenous fields, NMR imaging ofthe brain of small
laboratoryanimalsshouldbecomeaviableresearchtool.
Normal Structure of Cellular
Elements of the Brain
Supporting Cells
The cellular elements of the central nervous system
consist ofthe neurons and a variety ofsupporting cells.
The present account will focus on the supporting cells,
since these are the elements most commonly involved
in the formation of tumors in the brain.
NeuroglialCells. The neuroglial cells are generally
considered to be of three main types, astrocytes, oli-
godendrocytes, and microglial cells.
Astrocytes occur throughout the brain substance and
are of two varieties, protoplasmic and fibrous. Proto-
plasmic astrocytes are present in grey matter and fi-
brous astrocytes in white matter. Both have a pale cy-
toplasmand apartfromlocation, one differencebetween
them is that fibrous astrocytes contain more 8 to 9 nm
filaments than the protoplasmic ones. Both varieties
have processes which pass between the neuronal ele-
ments and some of these processes end in expansions
which form a glial limiting membrane on the outside of
the brain and around penetrating blood vessels. Gap
junctions are common between astrocytes and the num-
ber of gap junctions seems to be reduced between as-
trocytesinvolvedintheformationoftumors. Astrocytes
readily become edematous and can act as phagocytes.
Oligodendrocytes occur in both white and grey mat-
ter. They are more common in white matter since their
principal function is to form myelin sheaths. Each oli-
godendrocyte forms a number of internodal lengths of
myelin, the sheaths being produced at the ends of the
processes extending from the cell body.
Microglial cells are small cells with an electron mi-
croscopic appearance similar to that ofoligodendroglia.
During aging microglial cells accumulate lipofuscin and
they respond to disruptive events such as trauma, le-
sions, and inflammation bydividingand becomingphag-
ocytic. There is evidence to suggest that when blood
vessels are disrupted monocytes may enter the brain
and assume a morphology similar to that ofthe microg-
lial cells which normally inhabit the brain.
Ependymal Cells. The ventricles of the brain are
lined by an epithelium, the ependyma. The cells form a
single layer and are ciliated, producing movements of
the cerebrospinal fluid. Adjacent ependymal cells are
joined by gap junctions and zonulae adherences. Cere-
brospinal fluid can pass between ependymal cells to pro-
vide the interstitialfluid ofthe brain substance. In some
areas, the cells beneath the ependyma, the subepen-
dymal cells remain, mitotically active and can generate
neuroglial cells postnatally.
Choroid Plexus. The choroid plexus forms a se-
cretingepithelium whichis derived fromthe ependyma.
However, the choroidal cells have few cilia and instead
are covered by microvilli. The function of the choroid
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plexus is to secrete cerebrospinal fluid. To ensure that
fluid passes through and not between cells, adjacent
choroidal cells are joined together by tight junctions at
their ventricular ends. The blood vessels in the stroma
of the choroid plexus are unusual, for they are fenes-
trated. It is ofinterest that free macrophages, the Kol-
mer cells, lie on the ventricular surface of the choroid
plexus.
Aids to the Anatomic Pathology of
Brain Tumors
Electron Microscopy
Since electron microscopy can resolve difficult diag-
nostic and taxonomic problems, it is a potentially val-
uable tool in the diagnosis of natural and experimental
brain tumors. As currently applied, the utility of this
technique depends largely on its ability to resolve sub-
cellular organelles ofdiagnostic interest. The presence
andspecificity ofthese organelles, however, variesfrom
lesion to lesion and from cell to cell. On one hand are
those, such as synapses, premelanosomes, and neu-
rosecretory granules that are specific for a certain type
of cell and can establish, by themselves, a pathologic
diagnosis. Attheotherextreme aretheundifferentiated
lesions which lack specific ultrastructural features
which unfortunately are more frequent. Intermediate
are the common neoplasms with organelles such as cell
junctions, cytoplasmic filaments, microtubules, micro-
villi, and cilia which, although not specific for a certain
cell type, are helpful when considered with the light
microscopic features and location of the lesion.
To assess the contribution of electron microscopy to
the diagnosis of central nervous system neoplasia, sur-
gical specimens previously studied ultrastructurally
were reviewed for a 5-year period. During this time,
59 cases had been examined; 30 had been studied by
electronmicroscopyprimarilyforteachingpurposesand
29 were studied as part of the formal diagnostic work-
up. Foreach case, theusefulness ofelectronmicroscopy
was estimated. This was done in a semiquantitative
fashion, assigning 0 for cases in which electron micros-
copy provided no additional diagnostic information, to
4+ when electron microscopy provided a definitive di-
agnosis. A 1 + was assigned when the lesion provided
some additionalinformationtothelightmicroscopy, and
often served toreinforcethelightmicroscopicdiagnosis.
A 2+ was given when electron microscopy obtained
significant information in addition to the light micro-
scopic findings. A 3+ was given when the electron mi-
croscopy added more significant information to the light
microscopic findings, and the two techniques in com-
bination permitted a definitive diagnosis.
Ofthe29 cases studied aspartoftheformaldiagnosis,
electron microscopy was not felt to make a significant
contribution in 16. Ofthe remaining 13 cases, there was
one, a small cell neoplasm of the filum terminale with
neurosecretory granules in which the electron micro-
scopic findings established a neuroendocrine neoplasm.
This lesion was given a 4+. Two lesions were assigned
to 3+. These were a papillary meningiomain which the
classic ultrastructural features of meningioma was ap-
parent, and a nerve sheath myxoma ofthe vagus nerve
ina9-year-oldwherethemultiplebasementmembranes
were a significant finding. Two lesions, a meningioma
and achoroid plexus carcinoma, were assigned 2+. The
remaining seven lesions were given a 1+ in light ofthe
small contribution made by electron microscopy.
It is concluded from the above that electron micros-
copy as applied to human tumors can be a valuable tech-
nique and make a significant contribution to pathologic
diagnosis. However, if the present cases are repre-
sentative, its contribution will frequently be limited.
This, when considered with the necessary time and ex-
pense, suggests that electron microscopy be used ju-
diciously in the diagnosis of human brain tumors.
Immunohistochemistry
Immunohistochemistry is a useful technique for the
demonstration of a specific antigen in fixed or frozen
tissue. It requires a polyvalent antiserum or a mono-
clonalantibodyprepared againstthe antigenofinterest.
Immunofluorescence is generally used for frozen tissue,
and immunoperoxidase (PAP method) for formalin-
fixed, paraffin-embedded tissue. This technique can be
useful in the diagnosis of brain tumors provided the
specificity of the antiserum or monoclonal antibody is
well characterized. Structural antigens, such as the in-
termediate filament (IF) proteins, are generally com-
parably expressed in normal and neoplastic cells ofthe
same origin. Other antigens, particularly metabolic
markers, may have a different distribution in neoplastic
cells from that observed in their normal counterparts,
and caution must therefore be exercised in the inter-
pretation of the tumors expressing these markers.
The most important and reliable markers for the di-
agnosis of brain tumors appear to be the IF proteins.
The neurofilament proteins (NF) are expressed only in
tumors of putative neuronal origin or with presumed
neuronal differentiation (17). They are often not ex-
pressed in poorly differentiated malignant tumors as-
sumed to be of neuronal origin, such as central neuro-
blastoma, medulloblastoma, and pineoblastoma. They
are easily demonstrable inthe ganglion cell components
of gangliogliomas (18), but in that case they will add
little new information.
GFAPis the most commonlyused andbyfarthe most
useful to date ofthe immunohistochemical markers for
CNS tumors (18). It is found in all variants of astro-
cytoma, in astroblastomas, ependymomas, subependy-
momas, and in the astrocytic cells of mixed gliomas,
gangliogliomas, mixed gliomas and sarcomas, glioblas-
tomas, medulloblastomas, and pineocytomas (19).
The other IF proteins, although not exclusive to the
nervous system, maybeusefulincertaincircumstances.
Metastatic carcinomas may be detected or confirmed by
the demonstration of cytokeratin(s). Vimentin is pres-
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ent in lymphoma, melanoma, nonmuscle sarcoma, men-
ingioma, schwannoma, and fibrous histiocytoma cells,
as well as some ependymomas and anaplastic astrocy-
tomas. Desmin is found in rhabdomyosarcomas and
leiomyosarcomas (18,20).
A less reliable, but occasionally useful, marker for
CNS tumors is the S-100 protein. It has been demon-
strated in glial and meningeal tumors, but it has also
been found in a variety ofunrelated extraneural tissues
(21). Its main use in neuro-oncology appears to be in
the recognition ofamelanotic melanoma and ofSchwann
cell tumors.
Neuron-specific enolase (NSE) is an isozyme of the
glycolytic enzyme enolase which in normal conditions
is specifically localized in the cytoplasm of neurons
and neuro-endocrine cells. It can, however, be dem-
onstrated in neoplastic cells of various other tissues,
including cerebral tumors such as glioblastoma, as-
trocytoma, oligodendroglioma, ependymoma, medul-
loblastoma, pineocytoma, meningioma, and choroid
plexus papilloma (22). By electron microscopic im-
munocytochemistry, all brain tumors examined (pri-
mary and metastatic) have exhibited membrane stain-
ing for NSE, and many glioma cells have positively
stained intracellular filaments. NSE could notbe dem-
onstrated on membranes or filaments ofnormal brain
cells.
A useful glycolipid marker for oligodendrogliomas
could be galactocerebroside (23). The application of
myelin basic protein (MBP) for this purpose has so far
not been successful (18).
In addition, there are a number of potentially useful
antigens for brain tumor diagnosis. These include syn-
aptin, Di, D2, D3, Ran-1, a-2-glycoprotein, thy-1,
HNK-1, and some unnamed antigenic markers, whose
antisera selectively bind to neural elements. Full char-
acterization ofthese antisera and a study oftheir spec-
ificity for both normal and neoplastic brain tissue cells
is essential prior to their use for diagnostic purposes.
Monoclonal and Polyclonal Sera
A number of normal brain and nervous system anti-
gens have been identified by several investigators using
heterologous antisera raised against whole brain, cer-
tain areas of the brain, proteins isolated from brain
tissue or the retina (24,25). Among the best character-
ized are GFAP, MBP, NF proteins, NSE, and S-100
protein. GFAP, present only in astrocytes and in no
other neural or non-neural cell in the CNS, has found
wide spread use as a reliable marker aiding in the di-
agnosis of gliomas. Galactocerebroside, the major gly-
colipid in myelin, has been shown to be a specific cell
surface markerfor cultured oligodendrocytes (24). Rab-
bit antigalactocerebroside sera bound specifically to cul-
tured oligodendrocytes and this activity could be com-
pletely removed by absorption with myelin or
oligodendroglia. Gradient-purified cell populations en-
riched for human, rat, and lamb neurons or oligoden-
droglia has been used to raise rabbit antisera (26). Ex-
tensive cross-absorptions coupled with an indirect
immunofluorescence analysis revealed the presence of
cell type-specific surface membrane antigens. Antineu-
ronal sera reacted predominantly with neuronal cells
but not with other cell types. The anti-oligodendroglia
sera were, likewise, demonstrated to be specific, al-
though none ofthe antisera reacted with purified mye-
lin. Stallcup and Cohn (27)raisedrabbitantiseraagainst
two neuronal and two glial tumors induced by ethylni-
trosourea (ENU) in rats. Cross-absorption analyses re-
vealed subsets of specific surface antigens on rat neu-
ronal cells (Ni, N2, N3) and glial cells (Gi, G2). Using
an antiserum raised against a methylcholanthrene-in-
duced mouse glioma, Schachner (25) identified a brain-
specific antigen, NS- 1, that was enriched in adultwhite
matter but reduced in a myelin-deficient mutant strain
ofmice. The NS-1 antigen was expressed more in glial,
but not in neuron, enriched cell fractions and was found
only on glial tumor cells and not on those of neuronal
origin. Clearly, heterologous antisera can be produced
that will detect antigens unique to various cell types
found in normal neural tissue. All of these sera, how-
ever, require extensive cross-absorptions that result in
lowertitersofantibody offunctional, not absolute, spec-
ificity. We have produced and partially characterized a
panel of mouse hybridoma cell lines secreting mono-
clonalantibodies tobovine S-100protein. S-100hasbeen
demonstrated in astrocytes within the central nervous
system and in Schwann cell and satellite cells of the
dorsal root and autonomic gangliawithin the peripheral
nervous system. Six ofthese antibodies have been used
to demonstrate patterns ofdistribution ofS-100 protein
in formalin-fixed, paraffin-embedded sections of rat,
mouse, bovine, and human normal brain tissue by im-
munohistochemical staining by the avidin-biotin im-
munoperoxidase technique. These antibodies do not
react with the calcium-binding proteins, calmodulin or
parvalbumin, but do react with a copper-binding pro-
tein, neurocuperin. S-100 has been consistently dem-
onstrated by immunohistochemical staining in human
neoplasms ofastrocytic, Schwann cell, and melanocytic
origin and we have used some of these monoclones to
demonstrate S-100inhumanneuroglialtumors(schwan-
nomas, neurofibromas and astrocytomas) as well as in
Schwann cells and Langerhans' cells in human skin.
Morphology and Classification of
Brain Tumors in Man and Animals
Man
A major objective ofany classification ofneoplasia is
to provide an estimate ofbiologic behavior and patient
prognosis. Therefore, although morphology must con-
stitutethe cornerstone oftumorclassification, otherfac-
tors such as patient age, tumor location, involvement
of vital structures, intracranial mass effect, and tumor
evolution must alsobe considered. Tumor evolution and
progression are especially important: neoplastic trans-
formation may occur at different stages ofneuroepithe-
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lial cell differentiation and subsequent tumor evolution
may result in multiple cell populations that are pheno-
typically heterogeneous.
The classification of human brain tumors developed
by the World Health Organization (WHO) is based pri-
marily on cytological and histological characteristics
(28). Tumors are divided info those arising from neu-
roepithelial, nerve sheath, meningeal, lymphocytic, vas-
cular, germ cell, or malformative tissues. Neuroepithe-
lial tumors are subdivided into astrocytic,
oligodendroglial, ependymal, pineal, neuronal, and un-
differentiated (embryonal) tumors.
Astrocytomas may be classified as fibrillary, proto-
plasmic, gemistocytic, orpilocytic according to the mor-
phology of the predominant cell type. The cystic and
solid cerebellar astrocytoma, the pilocytic astrocytoma
ofjuvenile type, and the optic nerve glioma contain a
highproportionofpilocytic astrocytes. Theseneoplasms
may be associated with vascular proliferation and in-
vasion ofthe leptomeninges, but they are slow-growing
and possess a low potential for evolution into an ana-
plastic tumor. In contrast, the other types of astrocy-
toma exhibit more diffuse infiltration ofthe surrounding
brain and frequently evolve into an anaplastic astro-
cytoma or glioblastoma. Anaplasia is characterized by
high cell density, cellular and nuclear pleomorphism,
nuclear hyperchromasia, frequent mitoses, necrosis,
and vascular-mesenchymal proliferation.
The cells in oligodendrogliomas have round to oval
nuclei, clear cytoplasm and distinct cell boundaries.
There istypically afine vascular stromaseparatingclus-
ters of tumor cells. Ependymomas are also composed
of uniform cells with round to oval nuclei. Rosettes,
canals, and perivascular pseudorosettes are character-
istic. Anaplastic oligodendrogliomas and ependymomas
may be recognized, but as the tumors evolve, evidence
ofoligodendroglial orependymal differentiation may be
lost.
Undifferentiated (embryonal) tumors include the
glioblastoma, medulloblastoma, medulloepithelioma,
primitive polar spongioblastoma, and diffuse glioma.
The glioblastoma is ananaplastic neoplasm that exhibits
marked cellular and nuclear pleomorphism, necrosis,
and mesenchymal proliferation. Most glioblastomas ex-
hibit some degree of astrocytic differentiation, as evi-
denced by the expression of GFAP. Mixed glioma-sar-
comas are thought to arise from the secondary
neoplastic transformation ofhyperplastic mesenchymal
elements in a pre-existing glioblastoma. The medullo-
blastoma is a cerebellar neoplasm typically composed of
undifferentiated neuroepithelial cells. Some medullo-
blastomas, however, exhibit neuroblastic or neuroglial
differentiation. In diffuse gliomatosis, the neoplastic
cells exhibit such diffuse and extensive infiltration of
the brain that it is difficult or impossible to identify a
focal origin for the neoplastic process. The degree of
anaplasia is variable.
Tumors ofnerve sheath origin are the neurilemmoma
(schwannoma, neurinoma) and the neurofibroma. The
neurilemmoma exhibits a mixture of compact (Antoni
A) and spongy (Antoni B) areas. The neurofibroma is
characterized byirregularfascicles ofSchwann cellsand
fibroblasts.
Meningiomas are regarded as tumors arising from
cellular elements of the meninges. This view has re-
sulted in the inclusion of the hemangiopericytoma, a
vascular neoplasm, as a variant of meningioma. Other
variants include the meningotheliomatous, transitional,
fibroblastic, psammomatous, and angiomatous menin-
giomas, which are derived from arachnoidal cells. He-
mangiopericytic and papillary meningiomas exhibit
moreaggressivebiologicbehaviorthanothertypes. The
hemangioblastoma is a vascular neoplasm that occurs
mainly in the cerebellum, medulla, and spinal cord.
Primary lymphomas and several malformative brain
tumors are also recognized, including the craniopha-
ryngioma, epidermoid and dermoid cysts, colloid cyst,
and others. Neoplasm may also involve the brain by
direct extension from adjacent tissues or by hematog-
enous metastasis.
Domestic Animals
Brain tumors have been reported in all species of
domestic animals. As mentioned before, the most sig-
nificant incidence has been observed and reported inthe
dog and cat. This report is based on primary tumors
personally observed inthe dogwith commentson others
species when applicable. Our classification is based on
our interpretation of the predominate tumor cell type
and the site withinthe cranialcavity. Neuroglialtumors
were observed in 215 dogs. The breed incidence is sig-
nificant as 147 were in brachiocephalic breeds (boxer
104, Boston terrier 39, bull mastiff 2, English bull 1,
and pug 1). Age incidence was from 3 to 15 years with
160 between 6 and 11 years. The male/female ratio was
1.7. The tumors included 118 benign and malignant as-
trocytomas which were located in the cerebrum (80),
brainstem (20), cerebellum (17), and 1 originated in the
posterior pituitary. Four dogs had diffuse tumors ofthe
brain which were diagnosed as spongioblastoma or em-
bryonal glioma. There were 60 benign and malignant
oligodendrogliomas which were located in the cerebrum
(54) and brainstem (6). There were 25 dogs with glio-
blastoma multiforme located in the cerebrum (24) and
in the brainstem (1). Four ependymomas were noted in
the third ventricle (3) and cerebellum (1). Four dogs
had two or more primary tumors.
Twenty-five animals had tumors of the choroid
plexus. They occurred in 15 breeds and in 16 males and
9 females. The age range was from 2 to 11 years with
19 between 5 and 10 years. The site oforigin was fourth
ventricle (13), lateralventricle (4), third andlateralven-
tricle (4), and third ventricle (3). In one animal a gross
tumor was not apparent. Microscopically there was
meningeal carcinomatosis with carcinoma in situ pres-
ent in the plexus of the fourth ventricle. Two animals
were presented with pelvic limb paralysis which was
secondary to CSF metastasis with infiltration of the
lumbo-sacral spinal cord and nerve roots.
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Tumors of neuronal origin are rare in the dog. Two
medulloblastomas and one ganglioglioma were ob-
served.
Tumors of the meninges are common in the dog and
cat. Meningiomas were observed in 106 dogs (25
breeds). The age incidence wasfrom2and 15yearswith
62 between 6 and 12. The male/female ratio of0.6 sim-
ula-ted the human situation. The site was intracranial
(88), intraspinal (15) and intraorbital (3). The intra-
cranialmeningiomas inthe dog, whilehistologically sim-
ilar to man, manifested some significant variations.
These included a significant number ofbasal and plague
meningiomas involving the floor ofthe cranial cavity, a
marked incidence of brain infiltration via Virchow-Ro-
bins space, the frequent occurrence of focal necrosis
with suppuration and while occasionally observed,
psammoma bodies were not prominent. Electron mi-
croscopy illustrated interdigitations of cellular pro-
cesses, desmosomes, and tonofilaments. Meningeal sar-
comas were observed in 3 dogs.
Tumors of the cranial, spinal and peripheral nerves
were common in the dog. Sixty schwannomas were ob-
served which involved the cranial (4) and spinal (39) and
peripheral (17) nerves in 23 breeds of dogs. The age
incidence was from 2 to 17 years with 43 between 5 and
12 years. The male/female ratio was 2.3. There were 39
involving the spinal cord originating from the roots or
brachial plexus and sciatic nerves. Not included in this
series are 4 animals with intraparenchymal tumors
which were believe to be schwannomas (midbrain 1,
spinal cord 3).
Laboratory Animals
Mice. Swenberg (4) reviewed the literature con-
cerning neoplasms of the murine nervous system and
concluded that spontaneous brain tumors in mice were
extremely rare. There are a number ofreports ofspon-
taneous and experimentally induced brain tumors in
mice, some of which present detailed descriptions of
their morphologic characteristics. However, very few
publications present a review of the morphologic char-
acteristics of a range of neoplasms, and address the
question of their classification. Ward and Rice (29) re-
viewed brain tumors from a large group of rats and
mice, and proposed a simplified histogenetic classifica-
tion scheme. Morgan (30), examinedbrain tumors found
in 42 mice, from a study population of 77,410 mice at
the National Center for Toxicologic Research (NCTR),
andrecommended theuse ofthe newWHOclassification
(28).
Braintumors from alarge population ofmice, derived
from the National Toxicology Program (NTP archives),
were recently examined and classified, and the data
combined with that previously reported by Morgan et
al. (30). This study was based upon hematoxylin and
eosin stained sections from both treated and untreated
animals. Many ofthe tumors showed morphologic char-
acteristics reported by other workers for human brain
tumors (19,28), and were readily classified in the new
WHO scheme (31). Othersweremore difficultto classify
due to inadequate samples or unusual morphologic fea-
tures. A total of 17 lipomas were found, the majority
of which were in or adjacent to the midline. These tu-
mors were considered to be hamartomas rather than
true neoplasms. A total of 59 neoplasms, other than
lipomas, were found in the combined slide sets (NTP
and NCTR), of which over half were either oligoden-
drogliomas (27%) or meningiomas (31%). Other neo-
plasms diagnosed included medulloblastoma, glioblas-
toma, mixed glioma, ganglioglioma, choroid plexus
tumor, angiosarcoma, teratoma, and granular cell tu-
mor. It has yet to be established whether a common
system of classification is appropriate for brain tumors
of 'mice and men'.
Rats. The need for a histological classification of
brain tumors in rats became apparent in the early fifties
when research began to focus on the chemical induction
of brain neoplasms in this animal species (32). Unfor-
tunately, different classification schemes were intro-
duced by various research groups. They varied from
distinguishing neuroepithelial tumor types in iso-
morphic and pleomorphic subtypes including a grading
system forthe degree ofmalignancy to ones that simply
categorized all neuroepithelial neoplasms as gliomas.
The present situation is not much different, which is
mainly due to the fact that criteria for diagnosing brain
tumors in rodents are based on the general structure
ofthe neoplasm rather than on the cytological features.
The current availability of various nervous system
markers may lead to a more accurate classification
scheme or brain tumors in rodents in the near future.
Two tumor types occurringin rats are stillin dispute,
i.e., the granular cell tumor and malignant reticulosis.
The granular cell tumor is classified by some as a
meningioma and regarded by others to be a separate
entity. The histogenesis is still unknown (33,34). The
tumor is characterized by either sheets or nests of
closely packed large, round or oval cells with abundant
eosinophilic cytoplasm and aneccentricallyplaced, often
pleomorphic nucleus and a small nucleolus. The two
most characteristic features are the abundance ofsmall,
discrete, lightly eosinophilic cytoplasmic granules that
are PAS-positive and diastase-resistent and the pres-
ence of contact with the leptomeninges in nearly 100%
of the cases (Fig. 1). A morphologically similar tumor
occurs in man, but it is found most often in superficial
soft tissues or in the tongue and only incidentally in the
central nervous system. The cell of origin have been
considered to be the embryonic striated muscle cell,
fibroblast, histiocyte, Schwann cell, astrocyte, and a
undifferentiated mesenchymal cell. The conclusion of a
recent immunohistochemical and ultrastructural study
dealing with human granular cell tumors was that the
granularcellmaybederivedfromuncommittedpossibly
nerve-related mesenchymal cell. Recently, we per-
formed an immunohistochemical study on rat granular
cell tumors using S-100 protein and GFAP as markers.
The granular cell did not stain with either marker sug-
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FIGURE 1. Granular cell tumor in the cerebellum of a rat. Note the contact with the meninges. Hematoxylin-phloxine-saffron, x34.
FIGURE 2. Immunoperoxidase staining for S-100 protein. Negative staining of a granular cell tumor.
astrocytes at the margin of the tumor. x357.
gesting that the Schwann cell (Fig. 2) or the astrocyte
is not the cell of origin.
Another tumor type occurring in rats that is in dis-
pute is "malignant reticulosis." Krinke (35) found re-
cently that this tumortype was more common thanglial
Note positive staining of reactive
neoplasms in Sprague-Dawley derived rats. This con-
clusion was based on the use ofspecial stains including
immunohistochemistry, although they did not use anti-
Ig antibodies. They suggested that a number oftumors
diagnosed as glial neoplasms in rats are probably cases
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of reticulosis. The preliminary results of an immuno-
histochemical studyperformedbyuscannotexcludethis
possibility since a number of tumors that were diag-
nosed as astrocytomas were negative for GFAP (Figs.
3 and 4). Further studies, including the use of anti-Ig
antibodies, are necessary to substantiate this sugges-
tion.
Differentiation, Transformation and
Progression of Neuroglia Cells
Differentiation
Neoplastic disease essentially implicated populations
of cells ofrenewal, i.e., stem cells that lack the differ-
entiated characteristics ofthe tissue to which they give
rise but have the potential for the expression of these
characteristics and transmit this potential to theirprog-
eny. The potential is only fully realized in the post-
mitotic cells inthe terminal stage ofdifferentiation. Cell
replication is a prerequisite for malignant transforma-
tion. When the undifferentiated stem cell is the target
oftransformation, it is converted into a neoplastic stem
cell which to a variable extent has a capacity for diver-
gent differentiation similar to that of the normal stem
cell that has not been so transformed. In CNS tumors
this is illustrated by the group of central embryonal
neuroepithelial neoplasms, in which a correlation can be
drawn between the various tumor types and the se-
quential stages of neurocytogenesis occurring in the
forebrain.
A reserve population of stem cells capable offurther
differentiation in their progeny is present in all tissues
and organs actively involved in regular tissue renewal.
In the mammalian brain, as repeatedly shown in ex-
perimental neurooncogenesis, a highly susceptible tar-
get of neoplastic transformation are the migrating su-
bependymal cells, which are still cycling at a relatively
late stage of central neuroepithelial development, i.e.,
shortly before and after birth, and which are the glial
cell precursors whose progeny will later differentiate
into astrocytes and oligodendrocytes. One possible ex-
trapolation is that in human gliomas fetal neuroepithe-
lial cells in the late stages of pregnancy might be a
selected target for subsequent neoplastic development.
This would account for the relatively high incidence of
gliomas in childhood and is supported by a statistical
study of children with CNS tumors, in whom age at
diagnosis has been correlated with the risk of later re-
currence.
The reserve neuroepithelial cell population in the
adult human brain is low, but under the appropriate
stimulus astrocytes in Go phase are capable ofreenter-
ing the cycle and resuming proliferation. The main loci
ofcontinuingneurocytogenesis that maypersist inpost-
natal life may comprise the subependymal glial cell
layer; the "myelination glia" at the time of myelinoge-
nesis; the fetal external granular layer of the cerebel-
lum; the dentate fascia of the hippocampus; and, per-
haps, the subpial granular layer of the cerebral
hemispheres.
The nature, stage of differentiation apd differentiat-
ingpotential ofthe CNS cellstargetted bythefirst "hit"
of neoplastic tranformation will determine the type of
tumorthat will develop and the differentiatingpotential
of its cellular components. It must, however, be re-
FIGURE 3. Astrocytoma in the cerebrum of a rat. Nuclear pleomorphism and mitoses are present. Hematoxylin-phloxine-saffron, x357.
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FIGURE 4. Immunoperoxidase staining for GFAP. Negative staining ofthe neoplastic astrocytes whereas reactive astrocytes stain intensely.
x357.
FIGURE 5. Rat oligodendroglioma showing the characteristic honeycomb pattern and prominent vascular proliferation at the margin of the
lesion. (Hematoxylin-phloxine-saffron, x 147.
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membered that during the latent period of carcinogen-
esis, displacement ofthe targeted cells and their prog-
eny is likely to have occurred. Therefore, a glial
precursor cell "hit" in the course of its migration from
the subependymal zone could be the source ofa cortical
glioma in later life. In the experimental cerebellar med-
ulloblastomas induced in hamsters by the JC strain of
human polyoma virus, the transformed cells are pre-
sumed to be those ofthe external granular layer, which
retaintheirmitotic activity inthe course oftheirinward
migration: the tumors themselves appear to originate
from the internal granular layer.
Divergent differentiation in central neuroepithelial
tumors is most often expressed in embryonal neo-
plasms, such as the medulloepithelioma, the cerebellar
medulloblastoma, and the pineoblastoma. In differen-
tiated, relatively mature neoplasms, as in gangliog-
liomas, it is inferred to have resulted from the differ-
entiation of primitive bipotential precursor cells.
Curious examples illustrating the ontogenetic memory
expressed by the differentiation process are provided
by some pineoblastomas (fleurettes, indicating retinob-
lastic differentiation) and by choroid plexus papillomas
(GFAP expression).
Heterogeneity of malignant tumor cell populations,
long recognized as "anaplasia," is currently being em-
phasized not only as a phenotypic feature, but also as
an expression ofgenotypic (karyotypic) variability. Ge-
netic lability increases as the tumor becomes more ma-
lignant and is ascribed to the progressive increase in
mutation rates to which the resulting subpopulations
are subjected. The variability of GFAP expression in
tumorcell linesobtained fromhumangliomas and trans-
planted in athymic mice is consistent with the devel-
opment of subpopulations with different genetic prop-
erties.
There is considerable evidence that human malignant
disease is most often of monoclonal origin. Monoclon-
ality could be reconciled with the occasionally demon-
strated multicentricity of malignant gliomas and with
the existence of extremely diffuse forms (gliomatosis
cerebri) by assuming that, as the process of transfor-
mation is a progressive multistep event, the first mu-
tational "hit" might involve a single clone of neuroepi-
thelial cells in the course of their migration from the
primitiveventricularzone: afteravaryinglatentperiod,
the subsequent hit or hits necessary to promote tumor
formation would involve the multiple and distantly sep-
arated progeny of the originally targeted neuroepithe-
lial cell(s). A new kinetic round would be essential be-
fore the phenotypic development ofneoplasia.
Along a similar line of reasoning, divergent differ-
entiation with the development ofa mixed glioma com-
posed of well-differentiated cells could still be compat-
ible with monoclonality if the last mutational event
involved cells inthe preterminal stage ofdifferentiation
that were the progeny of an originally targeted pre-
cursor cell.
Neoplastic cell populations exhibit a dynamic state of
flux between differentiation and anaplasia. Cellular dif-
ferentiation is presumably determined by the ontoge-
netic memory of the cell clone originally hit, and is as-
sociated with a decycling of the proliferating
populations. Anaplasia, on the other hand, results from
the recruitment of proliferating cells from the nonpro-
liferating pool, and the progressive selection of clono-
genic subpopulations (36).
Progression
In man the early stages of neoplastic transformation
in the nervous system are poorly characterized (37).
This is in contrast to experimental animals where se-
quence studies of carcinogen-exposed brains have
shown how clusters of proliferating glial cells are fol-
lowed by development of microtumors and thereafter
larger, invasive tumors. So far, such studies on intact
brains have not enabled a closer examination of phen-
otypic changes at the cellular level.
Inordertoovercomethisproblem, aninvivo-invitro
system for the study of malignant transformation and
progression of fetal rat brain cells has been developed
(38). Pregnant BD IX rats were given a single IV in-
jection of 75 pug/g ENU at the 18th day of gestation.
One day afterwards the transplacentally exposed fetal
brains were transferred to long-term cell culture. The
cells underwent a characteristic sequence ofphenotypic
alterations endingwithtumorigenic properties after200
days in culture, i.e., the same period as it takes to
produce CNS tumors in ENU-exposed animals in vivo.
A survey of this sequence of malignant transformation
is given and discussed in relation to available data from
the development of intracranial tumors.
During the first 2 weeks of culture, ENU-exposed
brain cells had the same morphological appearance as
untreated control cultures although there was an in-
creased outgrowth ofdifferentiated neuroglial cells (oli-
godendrocytes, astrocytes, and neurons). The earliest
sign of morphological cell changes was after 3 weeks
when neuroglial cells exhibited large, dorsal ruffling
membranes, not oriented in the direction ofmovement.
After 60 days neuroglial cells grew in characteristic
organoid nodules consisting of astrocytes, oligodendro-
cytes and neurons extending to the periphery. At this
stage control cultures only consisted offlat, epithelioid
neuroectodermal cells.
The next stage was after 100 days with the onset of
rapid proliferation of morphologically "transformed"
cellswithatypicalnuclei, criss-crossgrowthpatternand
formation ofpile-up foci. Atthe same time amore stable
phenotype with expression ofmainly astrocyticmarkers
resulted. These cells were not tumorigenic by reim-
plantation into newborn rats. After 140 days loss of
anchorage dependence was observed as assayed by the
formation of agar colonies. Finally, after 2 to 300 days
the cells were biologically malignant as shown by the
formation of malignant, gliomalike tumors after reim-
plantation into isogeneic host animals. At the same time
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the cells showed invasionbyconfrontation with fetalrat
brain tissue in organ culture (39).
The resulting malignant cells contained glia-charac-
teristic markers as GFAP and S-100 protein, but in
addition exhibited NSE activity. The latter finding in-
dicates that ENU is acting on multipotent neuroecto-
dermal cells.
In conclusion, malignant transformation of fetal rat
brain cells inmonolayer culture is accompanied by early
morphological changes ultimately resulting in invasive-
ness and tumorigenicity.
Chromosomal Abnormalities
Our overall goal is to define the chromosomal abnor-
malities of malignant human gliomas and to determine
the theoretical and practical significance of these
changes. We have karyotyped 25 malignant human
gliomas including 3 anaplastic astrocytomas (AA), 21
glioblastoma multiforme (GBM), and 1 gliosarcoma(GS)
in direct preparation, short-term culture or both. Six
ofthese tumors (3 GBM) are near-tetraploid (group II)
and contain double minutes (DMs). Two ofthesetumors
are lacking two copies ofNo. 22; in the third, the chro-
mosomes are too short and poorly banded for specific
analysis. The remaining 16 tumors (1 AA, 14 GBM, 1
GS) have near diploid stemlines (group III). Eleven of
these sixteen tumors have gains ofnormal or abnormal
No. 7, 11 of them have losses of No. 10 and 10 have
both ofthese changes. Tentumors haveloss (3) orstruc-
tural rearrangements (7) of No. 9. In all seven cases
the breakpoint is at the centromere or in the p arm.
Ten group III tumors contain DMs.
Clinical and histologicparameters ofthese cases were
examined to determine if they could predict the kary-
otype or if it is an independent variable. The ratio of
males to females was approximately the same within
each group as it was for the overall series. All three
patients less than 40years old were ingroup I butthere
was otherwise no difference in age among the groups.
Group II tumors were more likely to have abundant
multinucleated giant cells, but not other histologic fea-
ture characterized any ofthe groups.
One explanation for the different karyotypic groups
is that they are related through progression. The kary-
otypes of three group III tumors which established in
culture showedthe same pattern ofevolution consisting
of doubling of the stemline or a closely related popu-
lation followed by acquisition of new markers; one line
changed again to near-pentaploid. These studies sug-
gest that group II tumors are at a later stage ofkary-
otypic progression than groups I and III. Long-term
studies are in progress to determine if patients with
group II tumors have a worse prognosis.
Among the other explanations for the different kary-
otypic groups of malignant human gliomas is the pos-
sibility that these specific chromosomal changes have
resulted in increased expression of particular onco-
genes. For example, ErbB is located on chromosome
No. 7. Tumors with extra copies of No. 7 may be car-
rying multiple copies of activated ErbB. The Sis on-
cogene is located on No. 22, and Abl on No. 9, but on
the q arm. It is possible that a previously undiscovered
oncogene is located on 9p and on 10. Losses of Nos. 9,
10, or 22 could allow expression ofan altered oncogene
on the remaining chromosome. Since many of the tu-
mors with chromosomal loss also contain DMs, these
bodies may contain amplified oncogenes. As human
gliomas are examinedfortheirexpression ofoncogenes,
the role ofspecific chromosomal abnormalities ofmalig-
nant human gliomas may be clarified.
Another explanation for the differing karyotypic pat-
tern ofhuman gliomas is that they may be produced by
different inducing agents. Both leukemia and sarcomas
induced in rats by DMBA contain gains and structural
abnormalities of No. 2 while Rous sarcoma virus-in-
duced rat sarcomas contain extra copies of No. 7. The
only similar data available for brain tumors show con-
sistent gains of No. 4 in cell lines derived from ENU-
inducedratbraintumors. Wehavebegunacomparative
study ofkaryotypes ofbrain tumorinduced in F344rats
with avian sarcomavirus (ASV), ENU and acrylonitrile
(AN). To date, six AN tumors have been evaluated-
2 have normal stemlines with occasional variant cells;
fourcontained no spreads for evaluation. As these stud-
ies are completed we will be able to determine if dif-
ferentinducingagentsproducedifferentkaryotypicpat-
terns among rat gliomas.
In summary, specific chromosomal abnormalities
characterize groups of human gliomas. These patterns
cannot be predicted using clinical or histologic param-
eters. Chromosomal composition may be useful in pre-
dicting prognosis or responsiveness to specific thera-
peutic agents. Alternatively, it may define groups of
gliomas produced by different inducing agents or may
identify tumors which carry the same activated onco-
gene.
Experimentally Induced Brain
Tumors
Chemically Induced
Brain tumors can be induced in experimental animals
by a broad series ofchemical carcinogens, ranging from
large polycyclic hydrocarbons to small alkylating
agents. The first experimental brain tumors were in-
duced by directly implanting pellets of methylcholan-
threne into the brains ofmice. This method was exten-
sively used for nearly 30 years, employing a variety of
species. Tumors arise in tissue adjacent to the pellet,
with the predominant tumortype depending on the site
ofimplantation. The primary advantage ofthis method
is the localization of the tumors.
In contrast to the polycyclic hydrocarbons, a new
groupofchemicalsthatinduced ahighincidence ofbrain
tumors following systemic exposure was identified by
Druckrey (40) and co-workersinthe 1960s. Beststudied
among these are MNU and ENU. Detailed investiga-
tions on the morphology, dose-response, pathogenesis
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and mechanisms of induction of brain tumors induced
by this family of carcinogens have been completed.
Only a small number ofthe other chemicals that have
been tested for carcinogenicity have induced brain tu-
mors in experimental animals. Oral or inhalation ex-
posure ofrats to acrylonitrile produced dose-related in-
creases in brain tumors tentatively classified as
anaplastic astrocytomas. A low, but dose-related in-
crease in tumors having a similar morphology has been
reported following inhalation exposure of rats to eth-
ylene oxide (41).
While gliomas have been induced by all ofthe chem-
icals listed above, it is ofinterest that no chemical has
been shown to cause granular cell tumors.
Virally Induced
Viruseshave beenimportant agents forexperimental
braintumorinduction sincethefirstexperiments in 1936
by Va'squez-Lo'pez (42) who showed that sarcomas
could be induced in the brains of chickens by intracer-
ebral inoculation of Rous sarcoma virus. Despite the
importance of oncogenic viruses as agents for experi-
mentalbrain tumorinduction spontaneous brain tumors
in either animals or humans have not been shown to be
caused by viruses. Endogenous retrovirus has been
demonstrated in a number of chemically induced intra-
cerebral tumors but the significance of that retrovirus
with regard to playing a role in transformation remains
to be demonstrated. In contrast to chemically induced
brain tumors there is a reasonably clear-cut association
with specific classes of viruses with the type of brain
tumors induced. The morphology of many of the brain
tumors induced following intracerebral inoculation of
virus is quite distinctive (43-45).
Most viruses must be inoculated intracerebrally in
high doses in neonatal animals for successful brain tu-
mor induction to occur. Nevertheless, Avian sarcoma
virus (ASV) and human papovavirus will induce brain
tumors following adult inoculation. The majority of vi-
ruses that induce brain tumors have been inoculated
across species barriers from the virus species oforigin,
and thus are in nonpermissive systems. No viral rep-
lication occurs although virus genome and virus-related
gene products are in the transformed brain tumor cells.
Some retroviruses (such as Simian sarcoma virus (SSV)
inprimatesandMurinesarcomavirus(MSV)inrodents)
havebeeninoculatedintracerebrallyinpermissive hosts
and virusreplication and fullgenome expression occurs.
The most widely used brain tumor models are the
ASV-inducedratanaplasticastrocytomafortherapeutic
and tumorbiological studies, andthelarge animalmodel
human papovavirus-primate and ASV-canine model for
imaging and diagnosis.
Table3 summarizestherange oftumortypes, viruses
and predominant hosts for experimental brain tumor
induction.
Radiation Induced
A group of rhesus monkeys is being observed in a
lifetime study ofthedelayed effects oftotalbodyproton
irradiation. The animals were each given a single dose
of one offive selected energies of protons covering the
spectrum ofenergies and doses to which anunprotected
astronaut might be exposed in space during a major
solar flare event. An unusual incidence of intracranial
neoplasms has been observed in a group of 72 rhesus
monkeys following exposure to 55 MeV protons. The
animals were two years ofage when exposed at the Oak
Ridge Isochronous Cyclotron during April, 1965. The
monkeys were confined in wire mesh cylinders and ro-
tated at 2 rpm in a proton beam perpendicular to the
spinalcolumn. Thedoseratewasapproximately50rads/
min and total doses ranged from 25 to 800 rads. The 55
MeV particle deposits all its energy in the first 2.5 cm
ofwet tissue, terminating in a "Bragg peak." Rotating
the subjects in the beam subjected a large volume of
brain tissue to Bragg peak proton irradiation. In the
subsequent 19-year period, eight monkeys exposed to
400 to 800 rads have developed similar fatal brain tu-
mors which were classified as glioblastoma multiforme.
Characteristic features ofthis tumor type were abnor-
mal mitoses, vascular proliferation, bizarre giant cells,
necrosis. and pseudopallisading ofnuclei. Only one nat-
urally occurring glioblastoma has been reported in a
rhesus monkey to date. At the present time 30 of the
original 72 irradiated animals in the 55 MeV group re-
main alive, and 8years have elapsed sincethelast gliob-
lastoma was diagnosed.
Conclusion
The increased incidence of brain tumors in man in
certain localities has suggested to some that exposure
to environmental chemicals has the potential to cause
brain tumors in man. We, therefore, felt it was worth-
while to review the brain tumors in the F344 rat and
B6C3F1 mouse, which are used as test animals in the
National Toxicology Program (NTP). Specifically, we
wanted to learn how frequently these tumors occurred
spontaneously, whether they could be induced and
whether these tumors had any similarity to brain tu-
mors in man.
Theincidence ofnaturallyoccurringbraintumorswas
only 1.1% in both male and females F344 rats when the
studies were terminated at 2 years. In lifetime studies
the incidence was 2.9% and 2.2% in males and females,
respectively. The incidence was fairly consistent be-
tween studies. The incidence never exceeded 4% (2/50
animals) for studies terminating at 2 years of age. The
tumors were even less common in mice (46).
Over 100 rat brain tumors were found in the NTP
collection. Each case was reviewed by one or more pa-
thologists and over 20 cases were reviewed by partic-
ipants in this workshop. Since many of these patholo-
gists were familiar with brain tumors in man and
domestic animals it was possible to draw some conclu-
sions about the rat lesions. First, we did not recognize
any rodent brain tumor as having the morphological
pattern ofglioblastoma multiforme as it occurs in man.
Yetinmany casesthe individual gliawerequite atypical
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Table 3. Specificity of virally induced experimental brain tumors.a
Experimental brain tumor type
Anaplastic astrocytoma glioblastoma
multiformeb
Pilocytic astrocytomas
Gemistocytic astrocytoma
Medulloblastoma
Neuroblastoma or retinoblastoma
Ependymoma
Choroid plexus papilloma
Meningioma
Sarcomas
Pineocytoma
Group
RNA oncornavirus
DNA papovavirus
DNA adenovirus
RNA oncornavirus
RNA oncornavirus
DNA papovaviruses
DNA adenoviruses
DNA adenovirus
DNA papovaviruses
DNA adenovirus
DNA papovaviruses
DNA papovaviruses
DNA adenovirus
DNA papovaviruses
DNA papovaviruses
DNA adenoviruses
RNA oncornaviruses
DNA papovavirus
(Mad-1,-4 strains)
Inducing viruses
Type
ASV, MSV, SSV
Human JC
SA-7
ASV.
MSV
Human JC
(Mad-1,-2 stains)
SA-7, HA-12
HA-12
Human JC
SA-7
SV-40, Human JC
SV-40, Human BK
CELO
Human JC
Bovine papilloma
Human JC
Murine polyoma
Bovine papilloma
SA-7, HA-12, HA-18
ASV, MSV
Human JC
Predominant host
Rats, dogs, primates
Rats, dogs
Mice
Hamsters
Rats
Hamsters
Hamsters
Cows
Hamsters, rats
Hamsters
aModified, from Walker and Bigner (45).
bGlioblastoma multiforme similar to the spontaneous human neoplasm with pleomorphic cells, endothelial proliferation, necrosis, and pseu-
dopallisading is a rare experimentally induced tumor, even in primates.
and less differentiated than the well differentiated glial
tumors in man.
Oligodendroglial tumors were quite common ana
were characterized by a prominent vascular prolifera-
tion often at the margin of the lesion (Fig. 3). Glial
tumors were frequently a mixture of astrocytes and
oligodendroglia and inthese cases vascularproliferation
was a usual feature. As in man, some tumors appeared
to be as almost pure population of astrocytes. It was
felt best to separate the tumors into astrocytomas,
mixed oligo-astrocytomas, and oligodendrogliomas.
There was no agreement onhowto separate these three
tumor types but one suggestion was that ifa tumor was
composed of 80% or more of one cell type it should be
given that diagnosis and reserve mixed for tumors
where the two cell populations varied between 20 to
80%. In any case, it is important when evaluating a
toxicological studytoclearly stateyourcriteriaandthen
be consistent throughout the study. The other tumors
found in the rat consisted of ependymomas, medullob-
lastomas, choroid plexus tumors, granular cell tumors
and meningiomas. The granular cell tumors were quite
characteristic (Fig. 1) and appear to arise in or be as-
sociated with the meninges.
An area of concern to toxicologists is focal lesions
consisting ofan increased number ofglial cells. In some
studies these have been called gliosis when the lesion
was too small to warrant a diagnosis of glioma even
though it resembles larger lesions that were diagnosed
asgliomas. Itwasnotedthatinmangliosisis considered
a reaction process and often an inciting factor can be
found. In man, small lesions are sometimes diagnosed
as incident glioma, especially when there is atypia of
the glial cells. With neurocarcinogens, such as ethyl-
nitrosourea, acrylonitrile and avian sarcoma virus, very
small microscopically detectable tumors or "pre-neo-
plastic" cellular proliferations are readily identifiable
and quite distinguishable from reactive gliosis. There
isnopresentlyknownneurocarcinogenwhichhasgliosis
as anintermediate transitional step as partofneoplastic
progression and transformation. It therefore is prudent
tomakethediagnosis ofgliosisonlyasareactiveprocess
which usually is associated with a clear structural ab-
normality such as infarct, abscess, hydrocephalus, or
encephalitis.
In man specific cellular markers such as GFAP and
S-100protein have proved useful inthe characterization
ofbraintumorsinman. Itwashopedthat similarresults
could be obtained in rats. Over60 ratbraintumors from
the National Toxicology Program were examined for
thepresenceofthesemarkersinDr. Bigner'slaboratory
at Duke University using immunoperoxidase tech-
niques. The rat brain tumors were uniformly negative
for both markers. It is known that tissue fixation and
handling can reduce antigenic determinants. All of the
material was formalin fixed, often for years. However,
in the tumors, reactive astrocytes strained strongly for
GFAP (Fig. 4) and S100 protein, suggesting fixation is
not the problem. Our current thought is that quanti-
tative expression for these two markers is less in rat
than in human brain tumors, and less than in reactive
astrocytes of rat.
Ultrastructural studies are oflimited value in the rat
especially in undifferentiated tumors. If specific ultra-
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structural features exist then electron microscopy can
be helpful. Anexample wouldbe differentiatinganame-
lanotic melanoma from a brain tumor. One diagnostic
aid that appears exciting is nuclear magnetic resonance
imaging. Currently, very clear brain images can be ob-
tained in the rat. This should allow one to detect early
lesions and follow the progression ofthe tumor.
The sensitivity ofthe F344ratandthe B6C3F1 mouse
to detect chemicals capable of causing brain tumors is
unknown. More than 300 chemicals tested routinely by
NCI/NTP in 2-year studies did not induce brain tumors
ofmice and only two (propyleneimine and propane sul-
tone) induced brain tumors in rats (29,47). Inboth cases
the rats were ofthe Sprague Dawley stock. Since brain
tumors are uncommon in the F344 rat and B6C3F1
mouse plus the fact that the control rates are very con-
stant, even a small chemically associated increase in
brain tumors may be quite significant.
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